Pharming Group is a small-cap biotech below the minimum investable market cap of $1 billion, with declining revenue of -8% but an exceptional Piotroski score of 8 out of 9, strong free cash flow conversion, and analyst targets implying 128% upside if momentum recovers.
Thesis pillars
- Below Investable Market Cap↓Deteriorating
- Revenue Decline Momentum Weakness↓Deteriorating
- High Piotroski Cashflow Quality→Stable
- +1 more pillar — see the Why tab for full reasoning
Pharming Group N.V. (PHAR) Stock Analysis
Falling Knife setup
Healthcare · Biotechnology
Sell if holding. Momentum 1.8/10 is below the 5.0 floor at $12.62 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Earnings expected to decline ~64% (cyclical peak); Weak overall score: 4.3/10.
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1... Read more
Sell if holding. Momentum 1.8/10 is below the 5.0 floor at $12.62 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Earnings expected to decline ~64% (cyclical peak); Weak overall score: 4.3/10. Chart setup: Death cross, below all MAs, RSI 20, MACD bearish. Score 4.3/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.
Recent developments
updated 2026-07-26Recent Developments — Pharming Group N.V.
Latest news
- NEWS Pharming Group Sets May 28, 2026 AGM With Key Governance and Capital Measures on Agenda - TipRanks — TipRanks neutral
- NEWS Pharming Group N.V. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:PHAR) 2026-05-07 - Seeking Alpha — Seeking Alpha neutral
- NEWS Pharming Posts Mixed Q1 2026 as Joenja® Growth Offsets RUCONEST® Decline and Global Label Expansion Advances - TipRanks — TipRanks positive
- NEWS PHAR - Pharming Group N.V. ADS each representing 10 stock news, filings & ratings - Quantisnow — Quantisnow neutral
- NEWS Pharming Group announces presentations at CIS 2026 Annual - GlobeNewswire — GlobeNewswire neutral
Generated 2026-07-26T09:57:02Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Revenue shrinking — -8.4% YoY. Growth thesis broken unless recovery story develops.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 1.8/10 is below the 5.0 floor at $12.62 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Earnings expected to decline ~64% (cyclical peak); Weak overall score: 4.3/10. Chart setup: Death cross, below all MAs, RSI 20, MACD bearish. Prior stop was $12.19. Score 4.3/10, moderate confidence.
Take-profit target: $29.20 (+131.5% upside). Prior stop was $12.19. Stop-loss: $12.19.
Earnings expected to decline ~64% (cyclical peak); Weak overall score: 4.3/10; Weak growth.
Pharming Group N.V. trades at a P/E of 70.1 (forward 192.6). TrendMatrix value score: 4.4/10. Verdict: Sell.
14 analysts cover PHAR with a consensus score of 4.4/5. Average price target: $34.
What does Pharming Group N.V. do?Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and...
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.